Lungenkarzinom

6 Studien
ADAURA2020Adjuvant Osimertinib in Resected EGFR-Mutated NSCLCCROWN2020Lorlatinib in Untreated ALK-Positive Advanced NSCLCFLAURA2018Osimertinib in Untreated EGFR-Mutated Advanced NSCLCPACIFIC2017Durvalumab Consolidation after Chemoradiotherapy in Stage III NSCLCKEYNOTE-0242016Pembrolizumab in PD-L1–High Advanced NSCLCIPASS2009Iressa Pan-Asia Study